Affordable Access

CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma.

Authors
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Volume
14
Issue
6
Pages
894–897
Identifiers
PMID: 12796027
Source
Medline
License
Unknown

Abstract

CD117 overexpression detected using immunohistochemistry is observed in about a third of patients with ESSCLC and does not have statistically significant prognostic value. However, CD117 may be a potential target for site-specific immunotherapy in ESSCLC. Our findings suggest a role for clinical trials assessing the role of selective tyrosine kinase inhibitor STI-571 (alone or in combination with conventional therapy) in patients with ESSCLC.

Statistics

Seen <100 times